Novartis has licensed a potential drug for Parkinson's from Belgium's UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback